Literature DB >> 32016055

The risks of converting post-hoc findings into primary outcomes in subsequent trials.

Filipe B Rodrigues1,2,3, Joaquim J Ferreira2,3,4.   

Abstract

Year:  2019        PMID： 32016055      PMCID： PMC6976501          DOI： 10.21037/atm.2019.09.105

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  25 in total

1.  Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease.

Authors:  Anders Lundin; Espen Dietrichs; Sara Haghighi; Marie-Louise Göller; Arvid Heiberg; Ghada Loutfi; Håkan Widner; Klas Wiktorin; Leif Wiklund; Anders Svenningsson; Clas Sonesson; Nicholas Waters; Susanna Waters; Joakim Tedroff
Journal:  Clin Neuropharmacol       Date:  2010 Sep-Oct       Impact factor: 1.592

Review 2.  Huntington's disease: a clinical review.

Authors:  P McColgan; S J Tabrizi
Journal:  Eur J Neurol       Date:  2017-09-22       Impact factor: 6.089

3.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

Authors: 
Journal:  Cell       Date:  1993-03-26       Impact factor: 41.582

4.  A polymorphic DNA marker genetically linked to Huntington's disease.

Authors:  J F Gusella; N S Wexler; P M Conneally; S L Naylor; M A Anderson; R E Tanzi; P C Watkins; K Ottina; M R Wallace; A Y Sakaguchi
Journal:  Nature       Date:  1983 Nov 17-23       Impact factor: 49.962

5.  Preparing for preventive clinical trials: the Predict-HD study.

Authors:  Jane S Paulsen; Michael Hayden; Julie C Stout; Douglas R Langbehn; Elizabeth Aylward; Christopher A Ross; Mark Guttman; Martha Nance; Karl Kieburtz; David Oakes; Ira Shoulson; Elise Kayson; Shannon Johnson; Elizabeth Penziner
Journal:  Arch Neurol       Date:  2006-06

6.  A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease.

Authors: 
Journal:  Mov Disord       Date:  2013-02-28       Impact factor: 10.338

Review 7.  Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations.

Authors:  Tiago A Mestre; Erik van Duijn; Aileen M Davis; Anne-Catherine Bachoud-Lévi; Monica Busse; Karen E Anderson; Joaquim J Ferreira; Philipp Mahlknecht; Vitor Tumas; Cristina Sampaio; Chris G Goetz; Esther Cubo; Glenn T Stebbins; Pablo Martinez-Martin
Journal:  Mov Disord       Date:  2016-10       Impact factor: 10.338

8.  International Guidelines for the Treatment of Huntington's Disease.

Authors:  Anne-Catherine Bachoud-Lévi; Joaquim Ferreira; Renaud Massart; Katia Youssov; Anne Rosser; Monica Busse; David Craufurd; Ralf Reilmann; Giuseppe De Michele; Daniela Rae; Ferdinando Squitieri; Klaus Seppi; Charles Perrine; Clarisse Scherer-Gagou; Olivier Audrey; Christophe Verny; Jean-Marc Burgunder
Journal:  Front Neurol       Date:  2019-07-03       Impact factor: 4.086

9.  Survival, Mortality, Causes and Places of Death in a European Huntington's Disease Prospective Cohort.

Authors:  Filipe Brogueira Rodrigues; Daisy Abreu; Joana Damásio; Nilza Goncalves; Leonor Correia-Guedes; Miguel Coelho; Joaquim J Ferreira
Journal:  Mov Disord Clin Pract       Date:  2017-05-26

10.  Rating Scales and Performance-based Measures for Assessment of Functional Ability in Huntington's Disease: Critique and Recommendations.

Authors:  Tiago A Mestre; Monica Busse; Aileen M Davis; Lori Quinn; Filipe B Rodrigues; Jean-Marc Burgunder; Noelle E Carlozzi; Francis Walker; Aileen K Ho; Cristina Sampaio; Christopher G Goetz; Esther Cubo; Pablo Martinez-Martin; Glenn T Stebbins
Journal:  Mov Disord Clin Pract       Date:  2018-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.